DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) today announced that they have signed a non-exclusive PER.C6® technology
research licensing agreement with Brazilian-based Recepta Biopharma S.A. This
agreement allows Recepta Biopharma to use the PER.C6® technology to develop
four antibodies it has licensed-in from the Ludwig Institute for Cancer
Research. Financial details were not disclosed.
About the PER.C6® Technology Platform
Crucell's and DSM’s
PER.C6® technology platform has been developed for the large-scale manufacture
of biopharmaceutical products including vaccines. Compared to conventional
production technologies, the strengths of the PER.C6® technology lie in its
excellent safety profile, scalability and productivity under serum-free
culture conditions.
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss
Exchange: CRX) is a biotechnology company focused on research, development and
worldwide marketing of vaccines and antibodies that prevent and treat
infectious diseases. Its vaccines are sold in public and private markets
worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B, a
fully-liquid vaccine against five important childhood diseases, and a
virosome-adjuvanted vaccine against influenza. Crucell also markets travel
vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine
and the only aluminium-free hepatitis A vaccine on the market. The Company has
a broad development pipeline, with several Crucell products based on its
unique PER.C6® production technology. The Company licenses this and other
technologies to the biopharmaceutical industry. Important partners and
licensees include DSM Biologics, Sanofi Aventis, Novartis, Wyeth and Merck &
Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in
Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over
a 1000 people. For more information, please visit www.crucell.com
